Article Text

Download PDFPDF

2022-RA-1550-ESGO Therapeutic effect of t-cell-derived nanovesicles in endometrial cancer
  1. Young Shin Chung
  1. Kyung Hee University Hospital at Gangdong, Seoul, Korea, Republic of


Introduction/Background T cell therapy, including adoptive T cell transfer and immune checkpoint blockades, is a remarkable advance in cancer immunotherapy, but its therapeutic effect on solid tumors is limited. A main cause of the low efficacy is T-cell exhaustion by immunosuppressive mechanisms of solid tumors, which are mainly mediated by PD-L1. To address some of the challenges faced by the current cancer mmunotherapy, we developed human T-cell-derived nanovesicles using a perfusable vascular network hydrogel with culturing patient tissues.

Methodology Human T-cell-derived nanovesicles produced by the serial extrusion of human cytotoxic T cells through membranes with nanosized pores that inhibit T-cell exhaustion and exhibit antitumoral activity maintained in the immunosuppressive tumor microenvironment are presented.

Results Similar to cytotoxic T cells, human T-cell-derived nanovesicles can be targeted at tumors via T-cell-membrane-originated proteins and kill cancer cells by releasing anticancer molecules such as granzyme B. Unlike cytotoxic T cells, human T-cell-derived nanovesicles are resistant to immunosuppressive molecules (e.g. PD-L1) of cancer cells by scavenging PD-L1, thereby preventing cytotoxic-T-cell exhaustion. Human T-cell-derived nanovesicles successfully inhibit tumor growth in a 3D human endometrial cancer chip using a perfusable vascular network hydrogel with culturing the same patients‘ tissues. Indeed, human T-cell-derived nanovesicles exhibit higher therapeutic efficacy than an immune checkpoint blockade in endometrial treatment.

Conclusion We propose to present these aspects of the human T-cell-derived nanovesicle to eventually improve the current cancer immunotherapy strategy and overcome the tumor’s immunosuppressive mechanisms.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.